Navigation Links
Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Date:9/3/2007

0.001).

The study also showed both treatment arms to yield similarly low rates of mortality and myocardial infarction. The mortality rates were 8.6 percent for the CYPHER(R) Stent and 7.9 percent for the bare metal stent (p=0.850), the Q- wave myocardial infarction rate for each treatment arm was 1.1 percent (p=1.00) and the non-Q-wave myocardial infarction rates were 7.4 percent for the CYPHER(R) Stent and 5.1 percent for the bare metal stent (p=0.388).

Also importantly, the study did not find a significant difference in the rates of stent thrombosis between the CYPHER(R) Stent and the bare metal stent, regardless of whether protocol or Academic Research Consortium (ARC) definitions were employed. When the protocol definitions were used, the rates of acute and subacute stent thrombosis were 0.0 percent for the bare metal stent and 1.1 percent for the CYPHER(R) Stent (p=0.25). The late stent thrombosis rates were 0.0 percent for the bare metal stent and 1.7 percent for the CYPHER(R) Stent (p=0.12). The definite/probable ARC definition identified a stent thrombosis rate of 4.2 percent for the CYPHER(R) Stent versus 1.7 percent for the bare metal stent (p=0.199). The definite/probable/possible ARC definition yielded a stent thrombosis rate of 6.5 percent for the CYPHER(R) Stent versus 3.5 percent for the bare metal stent (p=0.216). While there were numeric differences in the timing of such events between the CYPHER(R) Stent and the bare metal stent, at no point throughout the five-year period were the differences statistically significant.

"The results presented today reaffirm the long-term clinical benefits of the CYPHER(R) Stent compared to bare metal stents," said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical Officer, Cordis Corporation. "As previously announced, Cordis is expanding the E-SIRIUS Trial to eight years of follow-up to provide physicians with longer term data about the CYPHER(R) Stent that will assist them in making inf
'/>"/>

SOURCE Cordis Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
3. Cypher Sirolimus-eluting Coronary Stent Had Similar Results to Bypass Surgery in Long-Term Study of Patients With Multi-Vessel Coronary Artery Disease
4. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
5. New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
8. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
9. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
10. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
11. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... YORK , August 3, 2015 ... published by Persistence Market Research "Global Market Study ... to Witness Highest Growth by 2022", the ... US$15 Bn by the end of 2015 and is ... from 2015 to 2022, to account for US$23.7 ...
(Date:8/3/2015)... , August 3, 2015 ... is expected to reach USD 24.7 billion by ... View Research Inc. Growing prevalence of neurological and ... equipments market over the forecast period. The presence ... and cryotherapy, advancement in the technologies coupled with ...
(Date:8/3/2015)... , August 3, 2015 ... biotech companies, military surgical research and top-tier ... with regards to severe wound treatments for ... for regenerative medicine and tissue-engineered skin substitute ... and advancements in focus are Amarantus Bioscience ...
Breaking Medicine Technology:Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... , Infectious diseases researchers from the University of Pittsburgh School of Medicine are ... of HIV prevention drugs in sub-Saharan Africa. , A cooperative agreement awarded ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... to contract research organisations (CROs) for a slew of benefits, allowing them to ... and operations, boost quality with cost-effective utilisation of resources, get access to innovation ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... an agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine ... reduce health care costs. , Annually, more than 8.6 million adverse drug ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... Hispanic Health notes that while an overwhelming number of Hispanics believe people ... , The overwhelming 70 percent of participants queried said making diet changes was ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... solutions for drugs, biologics and consumer health products, today welcomed the announcement by ... OPKO’s New Drug Application for a new treatment for chronic kidney disease (CKD) ...
Breaking Medicine News(10 mins):Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3
... must weigh risks, benefits, experts say , , TUESDAY, Nov. ... data confirms that some common inhalers don,t boost the ... as chronic obstructive pulmonary disease (COPD). , In fact, ... in patients with COPD, the fourth biggest killer in ...
... 25 Nationwide Health Properties, Inc. (NYSE: NHP ) ... U.K. nursing home property company that may be in default ... the similarity of the names, it wanted to clarify that ... , Nationwide Health Properties, Inc. is a real ...
... (FRG) is pleased to announce the hiring of Dr. ... Operations. Katyal will be joining them from,West Penn Hospital, ... and Past President of the Pittsburgh Radiology Society. , ... widely regarded as the preeminent cardiovascular imager in,Western Pennsylvania. ...
... public event held today in New Orleans, the Department ... jointly announced the selection of adjacent downtown sites for ... projects, called the Veterans Affairs Medical Center and the ... greatly needed health care capability lost in New Orleans ...
... Nov. 25 The U.S. military provides its members ... commitments. But a researcher at Kansas State University ... be enough to maintain a supreme equilibrium. , ... of psychology at K-State, and colleagues have been studying ...
... components to determine levels of halogens , ... Minneapolis ... a leading materials testing laboratory, is helping companies adhere ... led to concerns regarding the environmental and health impact of halogens ...
Cached Medicine News:Health News:Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients 2Health News:Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients 3Health News:Foundation Radiology Group Adds World Class Cardiovascular Imaging Expert, Dr. Sanj Katyal, to Staff 2Health News:VA and Louisiana State University Announce Site Selections for New Orleans Medical Center Projects 2Health News:VA and Louisiana State University Announce Site Selections for New Orleans Medical Center Projects 3Health News:K-State Psychologist Studies Ways to Improve Soldiers' Work-Life Relationship 2Health News:Innovatech Labs, Assisting Companies in Adhering to Halogen-Free Manufacturing Standards Aimed at Protecting the Environment 2
Galilean Loupes...
... Over 40 cm field-of-view enables high-quality ... system with scalable 32-channel architecture. New powerful ... 3.0T imaging up to 80 mT/m ... SAR management to fully exploit the power ...
... fusion system represents a breakthrough for patients ... spine. The system gathers bone during decompression, ... of bone into the implant's chamber produces ... harvest from the iliac crest. The BAK/C ...
Signa Profile is built on the Signa foundation to deliver speed & image quality....
Medicine Products: